Year-end Report, January - December 2005

-Net sales amounted to MSEK 62.4 (86.7) -After tax, a net loss of MSEK 43.2 was reported (-16.8) -Earnings per share amounted to a loss of SEK 4.33 (-1.90) Key events during the fourth quarter of 2005 -Orexo listed on Stockholm Stock Exchange O-List and received gross proceeds of MSEK 333. -Orexo signed licensing agreement for RapinylTM (OX 20) for the European market. Key events after the close of the period -Orexo received first payment of MSEK 46.6, in January 2006, for the licensing agreement with ProStrakan Group plc relating to RapinylTM (OX 20) for the European market. For report in full format, see enclosed pdf. Financial hearings You are welcome to follow CEO Zsolt Lavotha´s presentation of the Year-end report at Operaterrassen in Stockholm, today February 23 at 4.00 p.m. You can also follow the presentation over the Internet. Language: Swedish, slideshow in English. For further information, please visit or For more information, please contact: Zsolt Lavotha, CEO, Tel: +46 (0)18-780 88 12, e-mail: Claes Wenthzel, Executive Vice President and CFO, Tel: +46 (0)18-780 88 44, e-mail: